GHB’s Path to Legitimacy: An Administrative and Legislative History of Xyrem

DSpace/Manakin Repository

GHB’s Path to Legitimacy: An Administrative and Legislative History of Xyrem

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Neuman, Ariel
dc.date.accessioned 2012-10-23T13:45:11Z
dc.date.issued 2004
dc.identifier.citation GHB’s Path to Legitimacy: An Administrative and Legislative History of Xyrem en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:9795464
dc.description.abstract This paper traces the path of a chemical compound (gamma-hydroxybutyrate, or GHB) from its status as an abused street drug to that of a legitimate, life-altering prescription treatment for a debilitating condition. It is the story of the public and private sectors working hand-in-hand to both protect the public from the detrimental effects of abuse while simultaneously ensuring that the thousands of Americans who need treatment are able to get it. It is also the story of an administrative and legislative system which, at least in this instance, seems to have worked to almost everyone’s satisfaction, despite the number of competing interests that were at stake. At the same time, this paper does not attempt to explain or evaluate medical claims about GHB or Xyrem. Instead, it is a historical account of the administrative and legislative path that led to GHB’s approval as a treatment for cataplexy related to narcolepsy. However, the paper does not take a linear approach to GHB’s history; instead the administrative and legislative processes are treated separately. Although the processes influenced each other in a myriad of ways, they were also distinct enough to require separate discussion. The story of Congress’ unprecedented bifurcated scheduling was surely a result, in part, of the success of Orphan’s clinical trials and pending New Drug Application (“NDA”), and the NDA was only allowed to go forward because of the bifurcated scheduling. Yet, to completely integrate the two stories would be needlessly confusing to the reader. en_US
dc.language.iso en_US en
dash.license LAA
dc.subject Food and Drug Law en_US
dc.subject FDA en_US
dc.subject GHB en_US
dc.title GHB’s Path to Legitimacy: An Administrative and Legislative History of Xyrem en_US
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-10-23T13:45:11Z

Files in this item

Files Size Format View
Neuman.pdf 208.1Kb PDF View/Open
Neuman.rtf 178.2Kb RTF file View/Open
Neuman.html 161.9Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters